Literature DB >> 3668116

Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma.

E Nassif1, M Weinberger, B Sherman, K Brown.   

Abstract

Extrapulmonary effects of alternate-day prednisone and inhaled beclomethasone dipropionate therapy were examined in 24 and 32 children with asthma, respectively. Early morning serum cortisol values were significantly lower among patients receiving alternate-day prednisone than among patients receiving inhaled beclomethasone dipropionate and control subjects at 24 hours but not at 48 hours after an alternate-day prednisone dose. Urinary-free cortisol output during the second 24 hours of the alternate-day prednisone regimen were similar to values among patients receiving inhaled beclomethasone and were significantly lower than among control subjects for both groups. Mean heights among patients before being placed on maintenance corticosteroids were at the thirty-fifth percentile and were similar for both regimens. This was significantly lower than initial measurements for control subjects who, on average, were near the fiftieth percentile for both children with asthma not requiring maintenance corticosteroids and normal healthy Iowa children. Mean heights for both corticosteroid-treated groups remained at the thirty-fifth percentile after more than a 2-year average duration of follow-up. Heights of children with chronic asthma not requiring maintenance corticosteroids were initially significantly higher (fifty-first percentile) than the patients who subsequently required maintenance corticosteroids and increased significantly to the sixty-first percentile during a mean 2.7-year follow-up. Heights of healthy Iowa children remained near the fiftieth percentile during a mean 7-year follow-up. Disproportionate weight gain, although it was not consistently present, was significantly more likely with the alternate-day prednisone. Other extrapulmonary effects of the corticosteroid regimens appeared not to be of clinical importance during the time period of the study.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668116     DOI: 10.1016/0091-6749(87)90002-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  16 in total

1.  Inhaled corticosteroids: benefits and risks.

Authors:  D M Geddes
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

2.  Asthma, inhaled corticosteroid treatment, and growth.

Authors:  T K Ninan; G Russell
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

Review 3.  Inhaled corticosteroids and cataract: prevalence, prevention and management.

Authors:  R G Cumming; P Mitchell
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 4.  Ocular toxicity of systemic asthma and allergy treatments.

Authors:  Leonard Bielory
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

Review 5.  Asthma and growth.

Authors:  G Russell
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

6.  Short-term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate.

Authors:  O D Wolthers; S Pedersen
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

Review 7.  Inhaled corticosteroid therapy in children: an assessment of the potential for side effects.

Authors:  G Russell
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

8.  Assessment of the systemic effects of inhaled glucocorticosteroids: the influence of blood sampling technique and frequency on plasma cortisol and leucocytes.

Authors:  B H Jennings; K E Andersson; S A Johansson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

9.  Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly.

Authors:  Salvatore Battaglia; Irene Cardillo; Federico Lavorini; Mario Spatafora; Nicola Scichilone
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 10.  Inhaled corticosteroids in children. Is there a 'safe' dosage?

Authors:  A L Boner; G L Piacentini
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.